Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Completed
Bayer
Phase 3
2013-01-01
The purpose of this study is to determine the best strategy to manage novel oral
anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators
hypothesize that performing device surgery without interruption of the novel oral
anti-coagulant will result in a reduced rate of clinically significant hematoma.
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Completed
Boehringer Ingelheim
Phase 3
2013-01-01
The purpose of this study is to determine the best strategy to manage novel oral
anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators
hypothesize that performing device surgery without interruption of the novel oral
anti-coagulant will result in a reduced rate of clinically significant hematoma.
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Completed
Bristol-Myers Squibb
Phase 3
2013-01-01
The purpose of this study is to determine the best strategy to manage novel oral
anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators
hypothesize that performing device surgery without interruption of the novel oral
anti-coagulant will result in a reduced rate of clinically significant hematoma.
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Completed
Heart and Stroke Foundation of Canada
Phase 3
2013-01-01
The purpose of this study is to determine the best strategy to manage novel oral
anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators
hypothesize that performing device surgery without interruption of the novel oral
anti-coagulant will result in a reduced rate of clinically significant hematoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
